NCT00470379View on ClinicalTrials.gov

Vaccine Therapy and Resiquimod in Treating Patients With Stage II, Stage III, or Stage IV Melanoma That Has Been Completely Removed by Surgery

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

April 30, 2006

Primary Completion Date

October 31, 2011

Study Completion Date

October 31, 2011

Conditions
Melanoma (Skin)
Interventions
DRUG

resiquimod

Escalating the dose of resiquimod applied to a fixed area of skin followed by application of topical NY-ESO-1b.

Trial Locations (1)

55905

Mayo Clinic, Rochester

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Mayo Clinic

OTHER

NCT00470379 - Vaccine Therapy and Resiquimod in Treating Patients With Stage II, Stage III, or Stage IV Melanoma That Has Been Completely Removed by Surgery | Biotech Hunter | Biotech Hunter